The HGF/Met signaling pathway is often thought of as one of the primary mechanisms of resistance to EGFR inhibitors and antiangiogenic therapies.46 EGFR is one of the most active growth factors that maintains tumor growth and survival in carcinomas. The gene discussed is MET; the disease is carcinoma.